Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus

A position statement of the Korean diabetes association

behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Original languageEnglish
Pages (from-to)423-429
Number of pages7
JournalDiabetes and Metabolism Journal
Volume41
Issue number6
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Type 2 Diabetes Mellitus
Hypoglycemia
Cardiovascular Diseases
Randomized Controlled Trials
Therapeutics
Hypoglycemic Agents
Weight Loss
Pharmacology
Insulin
Safety
Weights and Measures
Glucose
Glucagon-Like Peptide-1 Receptor

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association. / Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus : A position statement of the Korean diabetes association. In: Diabetes and Metabolism Journal. 2017 ; Vol. 41, No. 6. pp. 423-429.
@article{95e33a3746294f13b1ddbd6e4e36e7ac,
title = "Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: A position statement of the Korean diabetes association",
abstract = "The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.",
author = "{behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association} and Kim, {Hyun Jin} and Park, {Seok O.} and Ko, {Seung Hyun} and Rhee, {Sang Youl} and Hur, {Kyu Yeon} and Kim, {Nan Hee} and Moon, {Min Kyong} and byungwan lee and Kim, {Jin Hwa} and Choi, {Kyung Mook} and Kim, {Tae Nyun} and Lee, {Yong ho} and Kim, {Jin Hwa} and Hong, {Eun Gyoung} and Jaetaek Kim and Lee, {Won Young} and Bokrye Song and Kim, {Ji Young} and Yang, {Dong Hee} and Taeyoung Yang and Hyeongjin Kim",
year = "2017",
month = "12",
day = "1",
doi = "10.4093/dmj.2017.41.6.423",
language = "English",
volume = "41",
pages = "423--429",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "6",

}

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus : A position statement of the Korean diabetes association. / behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association.

In: Diabetes and Metabolism Journal, Vol. 41, No. 6, 01.12.2017, p. 423-429.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus

T2 - A position statement of the Korean diabetes association

AU - behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

AU - Kim, Hyun Jin

AU - Park, Seok O.

AU - Ko, Seung Hyun

AU - Rhee, Sang Youl

AU - Hur, Kyu Yeon

AU - Kim, Nan Hee

AU - Moon, Min Kyong

AU - lee, byungwan

AU - Kim, Jin Hwa

AU - Choi, Kyung Mook

AU - Kim, Tae Nyun

AU - Lee, Yong ho

AU - Kim, Jin Hwa

AU - Hong, Eun Gyoung

AU - Kim, Jaetaek

AU - Lee, Won Young

AU - Song, Bokrye

AU - Kim, Ji Young

AU - Yang, Dong Hee

AU - Yang, Taeyoung

AU - Kim, Hyeongjin

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

AB - The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

UR - http://www.scopus.com/inward/record.url?scp=85038876278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038876278&partnerID=8YFLogxK

U2 - 10.4093/dmj.2017.41.6.423

DO - 10.4093/dmj.2017.41.6.423

M3 - Review article

VL - 41

SP - 423

EP - 429

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 6

ER -